Navigation Links
Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug
Date:3/12/2008

TOKYO and SAN JOSE, Calif., March 12 /PRNewswire/ -- Oncolys BioPharma, Inc. (Tokyo, Japan) and Tacere Therapeutics, Inc. (San Jose, CA, USA) announced today that they have entered into a strategic alliance and license agreement to develop and commercialize throughout Asia, Tacere's RNA interference (RNAi)-based Hepatitis C virus (HCV) compound, TT-033, code-named by Oncolys as OBP-701. This agreement resulted from the strategic alliance entered into by Tacere and Oncolys in June 2007, whereby Oncolys was granted an option to acquire the Asian rights for TT-033.

"We are very pleased to be taking our relationship with Oncolys to the next level. After partnering TT-033 with Pfizer outside of Asia in December 2007, this agreement gives global scope to the development of TT-033/OBP-701 as a first-in-class treatment option for HCV patients," said Sara M. Hall, Chief Executive Officer of Tacere.

"We are extremely excited about solidifying this historic agreement with Tacere," said Yasuo Urata, President and Chief Executive Officer of Oncolys. "We recognized the power of this new approach to treating HCV and are delighted to see that the pharmaceutical industry has validated our investment in Tacere and this drug. More than ever, we believe that TT-033/OBP-701 will enable us to offer new treatments for patients suffering from HCV."

Under the terms of the agreement, Oncolys and Tacere will form a joint steering committee that will work with the Tacere and Pfizer steering committee to oversee preclinical research and development efforts for TT-033/OBP-701.

In addition to an up-front payment, Tacere will be eligible to receive milestone payments through successful achievement of development, approval, and commercialization milestones resulting in total potential payments to Tacere of up to $60 million. Upon commercialization of TT-033/OBP-701, Tacere would be entitled to receive royalties on net sales by Oncolys. Further, if Oncolys sublicen
'/>"/>

SOURCE Tacere Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... NC (PRWEB) September 19, 2014 ... Biobased Product Label for its Organic Cotton . ... product’s amount of renewable biobased ingredients meets or exceeds ... intermediate materials composed in whole or in significant part ... logo/label will allow our Organic cotton to be immediately ...
(Date:9/19/2014)... September 19, 2014 , The ... Society for Paediatric Endocrinology (ESPE) Meeting  Investment ... medical research in the field of growth  , ... Germany , today announced the first ... 2014. The awards were announced during a Satellite Symposium ...
(Date:9/18/2014)... 2014 HealthTronics, Inc ., ... radiology products and services, announced that a poster ... cryoablation) versus external beam radiotherapy (EBRT) is being ... Urological Association (MAAUA) Annual Meeting in Baltimore, Maryland ... of Cryosurgery and External Beam Radiation as Treatments ...
(Date:9/18/2014)... Worcester, Mass. (PRWEB) September 18, 2014 ... bore of an MRI scanner is currently being tested ... Brigham and Women's Hospital in Boston with the aim ... MRI images, can make prostate cancer biopsies faster, more ... The novel system also has the potential to deliver ...
Breaking Biology Technology:Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6
... the National Institute of Standards and Technology (NIST) ... new type of computer memory now under development. ... George Mason University (GMU), aims to optimize nanowire-based ... creating portable computers and cell phones that can ...
... In a new study conducted at the Pennington Biomedical Research ... activity over the past fifty years is a significant contributor ... caloric intake cannot solely account for observed trends in weight ... The study, entitled "Trends Over 5 Decades in ...
... 25, 2011 Rules-Based Medicine (RBM), a global ... Psynova Neurotech, has achieved a significant milestone in ... samples from a Roche clinical trial, the RBM ... a biomarker pattern was identified that has utility ...
Cached Biology Technology:NIST 'nanowire' measurements could improve computer memory 2Pennington Biomedical Research Center Study Suggests Decreases in U. S. Occupation Energy Levels a Significant Trigger of Obesity Epidemic 2Pennington Biomedical Research Center Study Suggests Decreases in U. S. Occupation Energy Levels a Significant Trigger of Obesity Epidemic 3Rules-Based Medicine Reaches a Significant Milestone in Companion Diagnostic Program With Roche 2
(Date:9/18/2014)... SAN ANTONIO, September 18, 2014 New research into ... which causes a severe hemorrhagic disease in humans similar ... factors essential for CCHFV infection. This discovery has the ... against the pathogen. , The research, reported ... PLoS Pathogens and conducted by scientists at the ...
(Date:9/18/2014)... that prompts millions of Americans to undertake jaunts into the ... a little longer within a century, according to new research. ... areas of the United States as summer temperatures linger later ... Global Ecology and Biogeography . For instance, the paper ... tree of New Hampshire could change color one to ...
(Date:9/18/2014)... Va.Sept. 18, 2014Many Americans across racial and ethnic ... greatest impact on their day-to-day life, more so ... hearing and speech (57% of African-Americans, 49% of ... Hispanics). When asked which disease or ailment is ... ranked first among African-Americans followed by AIDS/HIV. ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... the way carbon is counted in current U.S. climate legislation ... greenhouse gas emissions by using biofuels, says a premier group ... of biofuels made from biomass is huge, from both climate ... professor of crop and soil sciences and one of the ...
... Theodore Garland will give an hour-long lecture, titled ... p.m., Thursday, Oct. 29, in the University Theatre ... p.m. Seating is open. In his talk, Garland, a ... Riverside, will address the evolution of voluntary locomotor activity, some ...
... of Harvard chemists led by X. Sunney Xie has ... molecules with undetectable fluorescence. The room-temperature technique allows researchers ... offers broad applications in biomedical imaging and research. ... issue of Nature . Partial funding for the ...
Cached Biology News:Miscounting bioenergy benefits may increase greenhouse gas release 2Evolution of hyperactivity is focus of free public lecture at UC Riverside 2Seeing previously invisible molecules for the first time 2Seeing previously invisible molecules for the first time 3
... Rabbit polyclonal to MKK6 (phospho S207) ... applications). Antigen: ... around the phosphorylation site of Serine ... Entrez Gene ID: 5608 ...
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
CD45/CD34 combination 50 tests...
XPC Immunogen: XPC (NP_004619, 141 a.a. ~ 251 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: